220 related articles for article (PubMed ID: 21452186)
21. Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer.
Wang S; Zhang H; Scharadin TM; Zimmermann M; Hu B; Pan AW; Vinall R; Lin TY; Cimino G; Chain P; Vuyisich M; Gleasner C; Mcmurry K; Malfatti M; Turteltaub K; de Vere White R; Pan CX; Henderson PT
PLoS One; 2016; 11(1):e0146256. PubMed ID: 26799320
[TBL] [Abstract][Full Text] [Related]
22. Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo.
Guichard S; Arnould S; Hennebelle I; Bugat R; Canal P
Anticancer Drugs; 2001 Oct; 12(9):741-51. PubMed ID: 11593056
[TBL] [Abstract][Full Text] [Related]
23. Specificity of platinum-DNA adduct repair.
Chaney SG; Vaisman A
J Inorg Biochem; 1999 Oct; 77(1-2):71-81. PubMed ID: 10626357
[TBL] [Abstract][Full Text] [Related]
24. Spectrum of cellular responses to pyriplatin, a monofunctional cationic antineoplastic platinum(II) compound, in human cancer cells.
Lovejoy KS; Serova M; Bieche I; Emami S; D'Incalci M; Broggini M; Erba E; Gespach C; Cvitkovic E; Faivre S; Raymond E; Lippard SJ
Mol Cancer Ther; 2011 Sep; 10(9):1709-19. PubMed ID: 21750216
[TBL] [Abstract][Full Text] [Related]
25. Down-regulation of the nucleotide excision repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells.
Sabatino MA; Marabese M; Ganzinelli M; Caiola E; Geroni C; Broggini M
Mol Cancer; 2010 Sep; 9():259. PubMed ID: 20868484
[TBL] [Abstract][Full Text] [Related]
26. NDRG1 disruption alleviates cisplatin/sodium glycididazole-induced DNA damage response and apoptosis in ERCC1-defective lung cancer cells.
He L; Liu K; Wang X; Chen H; Zhou J; Wu X; Liu T; Yang Y; Yang X; Cui D; Song G; Wang J; Lei J
Int J Biochem Cell Biol; 2018 Jul; 100():54-60. PubMed ID: 29768183
[TBL] [Abstract][Full Text] [Related]
27. Multiple states of stalled T7 RNA polymerase at DNA lesions generated by platinum anticancer agents.
Jung Y; Lippard SJ
J Biol Chem; 2003 Dec; 278(52):52084-92. PubMed ID: 14534300
[TBL] [Abstract][Full Text] [Related]
28. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF.
Ferry KV; Hamilton TC; Johnson SW
Biochem Pharmacol; 2000 Nov; 60(9):1305-13. PubMed ID: 11008124
[TBL] [Abstract][Full Text] [Related]
29. [Effect of XPG down-regulation gene expression towards the proliferation of epithelial ovarian cancer cells and its chemosensitivity to platinum].
Zhang W; Wu FX; Wang Q; Li L
Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):286-91. PubMed ID: 22781116
[TBL] [Abstract][Full Text] [Related]
30. Superior cytotoxicity and DNA cross-link induction by oxaliplatin versus cisplatin at lower cellular uptake in colorectal cancer cell lines.
Virag P; Perde-Schrepler M; Fischer-Fodor E; Tatomir C; Dorneanu SA; Cernea VI; Irimie A
Anticancer Drugs; 2012 Nov; 23(10):1032-8. PubMed ID: 22614106
[TBL] [Abstract][Full Text] [Related]
31. Role of Nucleotide Excision Repair in Cisplatin Resistance.
Duan M; Ulibarri J; Liu KJ; Mao P
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291532
[TBL] [Abstract][Full Text] [Related]
32. XPG and XPF endonucleases trigger chromatin looping and DNA demethylation for accurate expression of activated genes.
Le May N; Fradin D; Iltis I; Bougnères P; Egly JM
Mol Cell; 2012 Aug; 47(4):622-32. PubMed ID: 22771116
[TBL] [Abstract][Full Text] [Related]
33. Cdt2-mediated XPG degradation promotes gap-filling DNA synthesis in nucleotide excision repair.
Han C; Wani G; Zhao R; Qian J; Sharma N; He J; Zhu Q; Wang QE; Wani AA
Cell Cycle; 2015; 14(7):1103-15. PubMed ID: 25483071
[TBL] [Abstract][Full Text] [Related]
34. Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours.
Cierna Z; Miskovska V; Roska J; Jurkovicova D; Pulzova LB; Sestakova Z; Hurbanova L; Machalekova K; Chovanec M; Rejlekova K; Svetlovska D; Kalavska K; Kajo K; Babal P; Mardiak J; Ward TA; Mego M; Chovanec M
BMC Cancer; 2020 Jan; 20(1):17. PubMed ID: 31906898
[TBL] [Abstract][Full Text] [Related]
35. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
[TBL] [Abstract][Full Text] [Related]
36. Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines.
Kitada N; Takara K; Minegaki T; Itoh C; Tsujimoto M; Sakaeda T; Yokoyama T
Cancer Chemother Pharmacol; 2008 Sep; 62(4):577-84. PubMed ID: 18030470
[TBL] [Abstract][Full Text] [Related]
37. Ataxia telangiectasia and rad3-related kinase contributes to cell cycle arrest and survival after cisplatin but not oxaliplatin.
Lewis KA; Lilly KK; Reynolds EA; Sullivan WP; Kaufmann SH; Cliby WA
Mol Cancer Ther; 2009 Apr; 8(4):855-63. PubMed ID: 19372558
[TBL] [Abstract][Full Text] [Related]
38. Regulation of endonuclease activity in human nucleotide excision repair.
Fagbemi AF; Orelli B; Schärer OD
DNA Repair (Amst); 2011 Jul; 10(7):722-9. PubMed ID: 21592868
[TBL] [Abstract][Full Text] [Related]
39. Trastuzumab and oxaliplatin exhibit a synergistic antitumor effect in HER2-postive gastric cancer cells.
Ding X; Qu X; Fan Y; Che X; Qu J; Xu L; Liu J; Liu Y
Anticancer Drugs; 2014 Mar; 25(3):315-22. PubMed ID: 24300914
[TBL] [Abstract][Full Text] [Related]
40. New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy.
Gentile F; Tuszynski JA; Barakat KH
J Mol Graph Model; 2016 Apr; 65():71-82. PubMed ID: 26939044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
